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Objective:  The  diagnosis  of  HPV-related  oropharyngeal  cancer  in clinical  practice  is based  on  p16 immuno-
histochemistry  and  PCR  detection  of  viral  DNA  (HPV-PCR).  The  primary  objective  of this  study was  to
evaluate  the  concordance  between  these  2 diagnostic  tests.  The  secondary  objective  was  to study  the
clinical  characteristics  of these  patients.
Materials  and  methods:  This  single-centre  prospective  study  was  conducted  between  February  2010  and
July  2012.  Immunohistochemical  analysis  of p16  and  HPV-PCR  were  performed  on  tumour  biopsies.
Concordance  was  evaluated  according  to  Cohen’s  kappa  coefﬁcient  and  was interpreted  according  to  the
Landis and  Koch  scale.  The  patients’  clinical  data  were  analysed  as  a function  of  the  diagnostic  test  results.
Results: Seventy-one  patients  were  included  in this  study.  The  prevalence  of HPV  was 43.7% according
to  p16  and  31%  according  to  HPV-PCR.  The  concordance  study  revealed  a kappa  coefﬁcient  of  0.615.  A
tumour  of  the  tonsil  or  base  of  the  tongue  was  detected  in 100%  of  p16+/HPV-PCR+  cases.  Smoking  and
alcohol  abuse  were  signiﬁcantly  less  frequent  among  HPV+ patients  regardless  of  the  method  of  detection.
These  patients  were  older  and  presented  tumours  with  a lower  grade  of  histological  differentiation.
Conclusion:  p16  immunohistochemistry  or HPV-PCR  used  alone  appear  to  be  insufﬁcient.  These  results
conﬁrm  the high  prevalence  of  HPV-related  oropharyngeal  squamous  cell carcinoma  (OSCC)  and  the
previously  reported  speciﬁc  clinical  and  histological  features,  apart  from  age.  It  appears  essential  for
future clinical  trials  to be  stratiﬁed  according  to smoking  and  tumour  HPV  status,  deﬁned  by means
of  reliable  virological  tests  targeting  E6/E7  mRNA  and  no longer  a simple  positive  response  to  the  p16
marker,  as  is  frequently  the case  at the present  time.  New  tests  suitable  for use in  routine  practice  therefore
need  to be developed.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
The association between upper aerodigestive tract squamous
ell carcinomas and human papilloma virus (HPV) infection has
een demonstrated since 1983 [1]. Subsequent epidemiologi-
al studies have demonstrated a growing predominance of HPV
nfection in oropharyngeal squamous cell carcinomas (OSCC),
articularly involving the tonsils. In the USA, the incidence of
∗ Corresponding author at: Centre Franc¸ ois-Xavier-Michelet, Hôpital Pellegrin,
lace Amélie-Raba-Léon, 33056 Bordeaux cedex, France.
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http://dx.doi.org/10.1016/j.anorl.2015.01.003
879-7296/© 2015 Elsevier Masson SAS. All rights reserved.HPV-positive OSCC increased by 225% between 1984 and 2004
while that of HPV-negative OSCC decreased by 50% over the same
period [2]. In 2011, the prevalence of HPV-positive OSCC in France
was 46.5% [3].
HPV-positive OSCC have a better prognosis than HPV-negative
OSCC. It has been demonstrated that HPV infection is an inde-
pendent prognostic factor, even in smoking patients, with a
58% reduction of the risk of death [4]. This difference can be
mainly explained by different oncogenetic mechanisms. A meta-
analysis published in 2013 demonstrated a signiﬁcant difference
in terms of overall survival and recurrence-free survival in favour
of patients with HPV-positive OSCC treated by radiotherapy with
or without chemotherapy and/or surgery [5]. Although changes to
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onventional treatment protocols may  be indicated in this partic-
lar patient category in the future, the modalities of these changes
ave not yet been deﬁned. At the present time, it is not recom-
ended to modify treatment decisions as a function of HPV status.
Before considering a possible modiﬁcation of treatment proto-
ols, a reliable virological diagnosis that can be performed in routine
ractice is absolutely necessary in order to accurately identify these
atients [6]. Various HPV diagnostic methods are currently avail-
ble. The gold standard accepted by most authors is detection of
iral oncoprotein E6 and E7 mRNA by quantitative PCR, which con-
rms the presence of transcriptionally active virus [7,8]. However,
his test is still expensive and difﬁcult to perform routinely. Detec-
ion of p16 overexpression is the most widely used test because it
s the least expensive and the easiest to perform [6]. However, this
est has a sensitivity of 94% but an insufﬁcient speciﬁcity of 82%
9]. Detection of HPV DNA by in situ hybridization or PCR are more
irect methods allowing characterization of the integrated or episo-
al  status of the virus and identiﬁcation of the serotypes involved
y genotyping, but routine use of these tests remains limited.
The primary objective of this study was to analyse the concord-
nce between the two diagnostic tests performed routinely in our
nstitution (detection of protein p16 overexpression by immuno-
istochemistry and detection of HPV DNA by PCR with genotyping)
n a population of patients referred for OSCC. The secondary objec-
ive was to more clearly deﬁne the clinical characteristics of this
opulation of patients with HPV-positive OSCC.
. Materials and methods
This single-centre prospective study was conducted between
ebruary 2010 and July 2012 in the Otorhinolaryngology and Head
nd Neck Surgery departments. All patients referred with histo-
ogically conﬁrmed OSCC were included. Biopsies were performed
uring upper aerodigestive tract panendoscopy under general
naesthesia. Two tumour biopsies were systematically performed.
he ﬁrst biopsy was ﬁxed in 10% formalin and was  sent to the
athology laboratory for histological and immunohistochemical
xamination. The second biopsy was placed in RNAlater® (Ambion)
nd was sent to the Virology laboratory, where it was  stored at 4 ◦C.
The following parameters were recorded for each patient: age,
ender, history of smoking, which was considered to be positive for
ngoing smoking or smoking cessation for less than 5 years greater
han or equal to 10 pack-years and a history of alcohol abuse, con-
idered to be positive for an alcohol consumption greater than
0 g/day in men  and 20 g/day in women. The anatomical tumour
ite, cTNM stage and grade of histological differentiation were also
ecorded. p16 and HPV-PCR status was determined from the tests
erformed.
.1. Determination of p16 status
Fixed tissues were parafﬁn-embedded then stained with
tandard haematoxylin-eosin stain for morphological diagnosis.
mmunohistochemistry screening for protein p16 was  system-
tically performed using the p16CINK4 murine monoclonal
ntibody (CINtec Technology Histology Kit clone E6H4) on a Dako
utostainer Plus® automat (Dakocytomation) with antibody incu-
ated for 12 hours, then revealed by the Envision® revelation
ystem (Dakocytomation). A negative control for p16 omitting the
rimary antibody was performed for each test. Slides were exam-
ned by the pathologist to evaluate labelling. Labelled samples were
valuated according to a binary classiﬁcation system left to the
athologist’s discretion, comprising “positive” and “negative” char-
cteristics.logy, Head and Neck diseases 132 (2015) 135–139
2.2. Determination of HPV-PCR status
Biopsies were ﬁrst treated in 20 mg/mL  SDS-proteinase K
buffer at 56 ◦C for 2 hours until complete digestion of the biopsy.
Nucleic acid extraction was performed on a MagNA Pure Compact®
automat (Roche Diagnostics) using the kit Pure MagNA Total
LC Nucleic Acids Insulation Kit® (Laboratory Roche Diagnoses).
After extraction, DNA was quantiﬁed by UV spectrophotometry
(NanoDropTM, Thermo Scientiﬁc). Viral DNA detection and PCR HPV
genotyping were performed with the INNO-LIPA HPV Genotyping
Extra System® kit (Innogenetics) and the results were interpreted
with LiRAS software. This technique allows the detection of 28
genotypes: 18 high-risk HPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 73, 82), 7 low-risk HPV (6, 11, 40, 43, 44, 54,
70) and 3 indeterminate-risk genotypes (69, 71, 74).
2.3. Statistical analysis
Cohen’s kappa correlation coefﬁcient was calculated between
the 2 tests studied with interpretation on a Landis and Koch scale:
between 0 and 0.20: very low concordance; between 0.21 and 0.40:
low concordance; between 0.41 and 0.60: moderate concordance;
between 0.61 and 0.80: satisfactory concordance; between 0.81 and
1: excellent concordance. Differences between groups were evalu-
ated by Chi2 test or Fisher’s exact test for categorical variables and
Student’s t-test for continuous variables. All statistical tests were
two-tailed and a P-value < 0.05 was  considered statistically signif-
icant. Statistical analysis was performed with SPSS Statistics 19.0
software (IBM Inc.).
3. Results
Seventy-one patients were included in the study. Patient char-
acteristics are described in Table 1. Protein p16 overexpression was
detected in 31 patients (43.7%). This p16+ group presented a signif-
icantly lower incidence of smoking and alcohol abuse (P < 0.001).
A signiﬁcant predominance of tumours of the tonsils and base of
the tongue was  observed in this group (P = 0.008). HPV-PCR iden-
tiﬁed a high-risk HPV in 22 patients (31%): HPV-16 in 20 cases,
corresponding to a prevalence of 28.2%, and HPV-33 in 2 cases. A
low-risk HPV-6 was  detected in 1 case. Smoking and alcohol abuse
were signiﬁcantly less frequent in the HPV-PCR+ group (P = 0.006
and P = 0.002, respectively). A tumour of the tonsil or base of the
tongue was detected in 100% of HPV-PCR+ cases (P = 0.001). All clin-
ical characteristics of the various groups according to their p16 or
HPV-PCR status are described in Table 2. These 2 tests were con-
cordant in 20 patients (81.7%) and discordant in 13 patients (19.3%).
The estimated kappa correlation coefﬁcient was 0.615, indicat-
ing a satisfactory concordance according to the Landis and Koch
scale.
The characteristics of p16+/HPV-PCR+ patients were compared
to those of the rest of the population. The mean age of p16+/HPV-
PCR+ patients was higher than that of the rest of the population
(62.8 vs. 55.5 years; P = 0.008). In contrast, smoking (55% vs. 88.2%;
P = 0.002) and alcohol abuse (20% vs. 68.6%; P < 0.001) were less fre-
quent in this group. All patients (100%) of the p16+/HPV-PCR+ group
presented a tumour of the tonsil or base of the tongue versus 64.7%
of the rest of the population (P = 0.002). This difference in terms of
tumour site was  even more signiﬁcant when the p16+/HPV-PCR+
group was compared to the p16-/HPV-PCR− group (P < 0.001).
Patient characteristics according to their combined p16 and
HPV-PCR status are presented in Table 3. Two  of the patients
with discordant p16 immunohistochemistry and HPV-PCR results
were p16-/HPV-PCR+ and 11 were p16+/HPV-PCR−. The charac-
teristics of p16+/HPV-PCR− patients were compared to those of
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Table  1
Clinical characteristics of all patients included.
Total
n = 71
Mean age (years) 57.5
Gender
Male 54 (76.1%)
Female 17 (23.9%)
Chronic smoking 56 (78.9%)
Chronic alcohol abuse 39 (54.9%)
Site
Tonsil 27 (38%)
Base of tongue 23 (32.4%)
Vallecula 7 (9.9%)
Posterior pharyngeal wall 7 (9.9%)
Soft palate 4 (5.6%)
Glossotonsillar sulcus 3 (4.2%)
Tumour grade
G1 well-differentiated 23 (32.4%)
G2 moderately-differentiated 35 (49.3%)
G3 poorly-differentiated 13 (18.3%)
cT stage
T1 6 (8.5%)
T2  29 (40.8%)
T3 15 (21.1%)
T4a 18 (25.4%)
T4b 3 (4.2%)
cN  stage
N0 10 (14.1%)
N1 6 (8.5%)
N2a 4 (5.6%)
N2b 24 (33.8%)
N2c 27 (38%)
N3 0 (0%)
p
o
o
a
T
C
HcM  stage
M0 68 (95.8%)
M1 3 (4.2%)16+/HPV-PCR+ patients. A statistically signiﬁcant difference was
bserved between the 2 groups in terms of tumour site, with 27.3%
f sites other than the tonsil or base of the tongue in the discord-
nt group (P = 0.037). Two p16-/HPV-PCR+ patients were smokers
able 2
linical characteristics of the patients as a function of p16 or HPV-PCR status.
p16+
n = 31 (43.7%)
p16−
n = 40 (56.3%)
Age (years) 58.71 56.6 
Smoking 18 (58.1%) 38 (95%) 
Alcohol 7 (22.6%) 32 (80%) 
Tumour site
Anterior/lateral oropharynxa 28 (90.3%) 25 (62.5%) 
Other  sites 3 (9.7%) 15 (37.5%) 
Tumour grade
G1/G2 21 (67.7%) 37 (92.5%) 
G3  10 (32.3%) 3 (7.5%) 
cTNM  stage
T
T1/T2 18 (58.1%) 17 (42.5%) 
T3/T4  13 (41.9%) 23 (57.5%) 
N
N0  2 (6.5%) 8 (20%) 
N+  29 (93.5%) 32 (80%) 
M
M0  30 (96.8%) 38 (95%) 
M1  1 (3.2%) 2 (5%) 
PV: human papilloma virus; NS: non signiﬁcant.
a Anterior and lateral oropharynx comprises palatine tonsil, base of the tongue and gloogy, Head and Neck diseases 132 (2015) 135–139 137
with a smoking history of 50 and 70 pack-years and an alcohol
consumption of 80 and 40 g/day, respectively.
4. Discussion
The results of this study show that the two diagnostic tests
performed routinely in our institution were not sufﬁciently con-
cordant, and that the use of only one of these tests would be
inadequate to reliably conﬁrm the viral origin of the carcinoma.
With these limitations in mind, our results conﬁrm the high
prevalence of HPV-positive OSCC and the clinical and histological
characteristics speciﬁc to this subpopulation of patients.
p16 overexpression detected by immunohistochemistry reﬂects
altered functioning of pRb induced by viral oncoprotein E7. This
altered functioning may  also be secondary to a mutation of the
pRb gene independent of HPV infection. In 2012, Thomas also sug-
gested the possibility of p16 overexpression unrelated to pRb [10].
This test therefore presents a risk of false-positive results, which
can explain the 11 discordant patients observed in the p16+/PCR−
group. Another hypothesis to explain these results would be the
failure of PCR to detect viral DNA, which could be explained by
non-recognition of the L1 sequence of the viral genome targeted
by complementary primers used for PCR. HPV would no longer be
detected in tumours in which genomic progression has resulted
in loss of identiﬁable viral DNA sequences [11]. In a retrospective
study of 108 patients, Schache et al. also reported these discor-
dances with 7% of p16+/HPV-PCR− patients [9].
PCR genotyping is a very sensitive technique, as it is able to
detect very small quantities of viral DNA, but it has a limited speci-
ﬁcity to identify the aetiopathogenesis of these tumours. PCR can
demonstrate simple HPV infection even in the absence of integra-
tion of the HPV genome with expression of E6 and E7. The high
sensitivity of PCR could explain its ability to detect viral DNA  con-
tamination of the sample during sample processing [9,10]. Such
contamination could explain the results observed in 2 patients of
the p16-/HPV-PCR+ group. The hypothesis of false-positive results
for these 2 patients is all the more likely in that they were both
heavy smokers and drinkers.
In our study, the statistical concordance between these 2 tests
was considered to be satisfactory according to the Landis and Koch
P HPV-PCR+
n = 22 (31%)
HPV-PCR−
n = 49 (69%)
P
NS 63.05 55.04 0.007
< 0.001 13 (59.1%) 43 (87.8%) 0.006
< 0.001 6 (27.3%) 33 (67.3%) 0.002
0.008 22 (100%) 31 (63.3%) 0.001
0 (0%) 18 (36.7%)
0.007 15 (68.2%) 43 (87.8%) 0.049
7 (31.8%) 6 (12.2%)
NS 11 (50%) 24 (49%) NS
11 (50%) 25 (51%)
NS 1 (4.5%) 9 (18.4%) NS
21 (95.5%) 40 (81.6%)
NS 22 (100%) 46 (93.9%) NS
0 (0%) 3 (6.1%)
ssotonsillar sulcus.
138 D. Fonmarty et al. / European Annals of Otorhinolaryngology, Head and Neck diseases 132 (2015) 135–139
Table  3
Patient characteristics as a function of combined p16 and HPV-PCR status.
p16+
HPV-PCR+
n = 20 (28.2%)
p16-
HPV-PCR−
n = 38 (53.5%)
Pb p16+
HPV-PCR−
n = 11 (15.5%)
Pc p16-
HPV-PCR+
n = 2 (2.8%)
Age (years) 62.8 56.13 0.15 51.27 0.17 59
Smoking 11 (55%) 36 (94.7%) 0.001 7 (63.6%) NS 2 (100%)
Alcohol  4 (20%) 30 (78.9%) < 0.001 3 (27.3%) NS 2 (100%)
Tumour site
Anterior/lateral oropharynxa 20 (100%) 23 (60.5%) 0.001 8 (72.7%) 0.037 0 (0%)
Other  sites 0 (0%) 15 (39.5%) 3 (27.3%) 2 (100%)
Tumour grade
G1/G2 13 (65%) 8 (72.7%) 0.23 2 (100%) NS 35 (92.1%)
G3  7 (35%) 3 (27.3%) 0 (0%) 3 (7.9%)
cTNM  stage
T
T1/T2 10 (50%) 8 (72.7%) NS 1 (50%) NS 16 (42.1%)
T3/T4 10 (50%) 3 (27.3%) 1 (50%) 22 (57.9%)
N
N0  1 (5%) 1 (9.1%) NS 0 (0%) NS 8 (21.1%)
N+  19 (95%) 10 (90.9%) 2 (100%) 30 (78.9%)
M
M0  20 (100%) 10 (90.9%) NS 2 (100%) NS 36 (94.7%)
M1  0 (0%) 1 (9.1%) 0 (0%) 2 (5.3%)
HPV: human papilloma virus. The p16-/HPV-PCR+ group was not compared to the other groups because of its small sample size; NS:  non signiﬁcant.
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b Comparison p16+/HPV-PCR+ vs. p16-/HPV-PCR−.
c Comparison p16+/HPV-PCR+ vs. p16+/HPV-PCR−.
cale (kappa correlation coefﬁcient of 0.615). However, this con-
ordance appears to be insufﬁcient in view of the prognostic and
otential therapeutic implications, with 18.3% of discordant results
etween p16 and HPV-PCR. In 2010, Ang also reported discordances
etween these two tests, with a correlation coefﬁcient slightly
igher than 0.8 [4]. The deﬁnitive diagnosis of HPV-related OSCC
herefore clearly cannot be based on only one of these 2 tests. The
old standard accepted by most authors is detection of viral onco-
rotein E6 and E7 mRNA. Smeets et al. were the ﬁrst to evaluate
 diagnostic algorithm using detection of p16 overexpression and
CR genotyping by comparing these methods to the gold standard.
hey reported 100% speciﬁcity and sensitivity with the follow-
ng algorithm: p16 immunohistochemistry for all tumours then
PV-PCR for p16 positive tumours [7]. Schache et al. reported a
ensitivity of 97% and a speciﬁcity of 94% for the p16/HPV-PCR
ombination compared to PCR detection of E6 mRNA [9].
Based on the positivity of these 2 tests, the prevalence of HPV-
elated OSCC in our study would be 28.2%. In 2011, in a French
ulticentre series of 523 patients, Lacau St Guily et al. reported
 prevalence of 46.5% based exclusively on PCR [3]. In the meta-
nalysis published by Kreimer et al., based on 27 studies (969
atients) all over the world, the prevalence of HPV-positive OSCC
ccording to PCR was 35.6% [12]. In contrast, in a prospective
eries of 68 cases of OSCC derived from Latin America, a region
n which smoking remains the leading aetiological factor, Ribeiro
t al. reported a prevalence of 4.4% by PCR [13]. The prevalence of
PV-positive OSCC is therefore largely inﬂuenced by the diagnostic
ethods used and the study population.
In our study, the clinical characteristics of p16+/HPV-PCR+
atient were remarkable from several points of view. Firstly, the
umour was systematically situated in the palatine tonsil or lin-
ual tonsils (base of the tongue). This predominance has already
een reported in many studies, regardless of the diagnostic test
sed [2,14,15]. Some authors have proposed the hypothesis that
onsillar crypts may  promote retention of viral particles [16]. Sec-
ndly, these patients presented a lower rate of smoking (55% versus
4.7%). It has been clearly demonstrated that smoking constitutes
n oncogenic factor independent of HPV infection [4,17]. In 2010,ssotonsillar sulcus.
Ang showed that the response to treatment of HPV-positive OSCC
decreased with increasing levels of smoking, thereby creating inter-
mediate risk proﬁles, although they were unable to deﬁne a critical
threshold [4]. Smoking induces speciﬁc genetic changes, which
modify the tumour response to treatment. Our study comprised
a limited description of smoking, preventing any subgroup analy-
sis according to the level of smoking. Thirdly, these patients were
older, which is in contradiction with most of the results published in
the literature [2,4,9]. This discordant result can be explained by the
speciﬁc geographic origin of our population. These results empha-
size that the viral origin of OSCC must be systematically considered,
regardless of the patient’s age and smoking status. Finally, these
patients’ tumours presented signiﬁcant histological differences
in terms of grade of differentiation, with less well-differentiated
tumours. The higher frequency of poorly-differentiated tumours
could be related to the speciﬁc nature of the tonsillar crypt epithe-
lium particularly targeted by HPV compared to the epithelium of
the rest of upper aerodigestive tract [16].
5. Conclusion
p16 immunohistochemistry or PCR detection of HPV viral DNA
combined with genotyping give discordant results. These tech-
niques are insufﬁcient when used alone to reliably conﬁrm the viral
origin of an OSCC. The combined use of these two tests would be
more reliable, but cannot eliminate all ambiguity. It appears essen-
tial for future clinical trials to be stratiﬁed according to smoking
status and tumour HPV status, which must be deﬁned by reli-
able virological tests targeting E6/E7 mRNA and no longer simply
based on positivity of the p16 marker, as is all too frequently the
case. New tests need to be developed before considering a possible
modiﬁcation of conventional treatment regimens for patients with
HPV-positive OSCC.Disclosure of interest
The authors declare that they have no conﬂicts of interest con-
cerning this article.
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